5AM Ventures IV, L.P.

Average Profitability
8.94%
Insider Buys Quantity
3
Insider Buys Sum
$23.91M
Insider Sells Quantity
8
Insider Sells Sum
$71.48M

Insider Activity of 5AM Ventures IV, L.P.

The largest purchase of all time was on 2019-05-28 and amounted to 1500000 shares of IDEAYA Biosciences, Inc. for $15M.

The largest sale of all time was on 2020-11-11 and amounted to 1600000 shares of IDEAYA Biosciences, Inc. for $21.86M.

Biography of 5AM Ventures IV, L.P.

No biography is available at this moment.

2020-11-11SaleIDEAYA Biosciences, Inc.
IDYA
10 percent owner
1.6M
5.7544%
$13.66$21.86M+60.63%
2020-10-05SaleAprea Therapeutics, Inc.
APRE
Former 10% holder
175,000
0.7844%
$25.30$4.43M-80.91%
2020-06-16SaleAprea Therapeutics, Inc.
APRE
Former 10% holder
140,000
0.6473%
$33.30$4.66M-38.45%
2020-06-11SaleAprea Therapeutics, Inc.
APRE
Former 10% holder
245,000
1.1106%
$28.75$7.04M-27.94%
2020-05-19SaleAprea Therapeutics, Inc.
APRE
Former 10% holder
255,000
1.3734%
$35.15$8.96M-20.89%
2019-10-07PurchaseAprea Therapeutics, Inc.
APRE
Former 10% holder
333,333
1.2152%
$15.00$5M+53.58%
2019-06-21SaleCrinetics Pharmaceuticals, Inc.
CRNX
500,000
0.9884%
$11.10$5.55M-19.41%
2019-05-28PurchaseIDEAYA Biosciences, Inc.
IDYA
10 percent owner
1.5M
16.0251%
$10.00$15M-37.23%
2019-03-18SaleCrinetics Pharmaceuticals, Inc.
CRNX
10 percent owner
309,678
1.2266%
$24.25$7.51M-13.3%
2019-01-22SaleCrinetics Pharmaceuticals, Inc.
CRNX
10 percent owner
524,306
2.2591%
$21.88$11.47M+9.87%
2018-07-20PurchaseCrinetics Pharmaceuticals, Inc.
CRNX
10 percent owner
230,000
0.8493%
$17.00$3.91M+10.46%
Company
About Prismo.proNewsPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.